NCT02437136 2025-03-20Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in Non-small Cell Lung Cancer (NSCLC) With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer (CRC)Syndax PharmaceuticalsPhase 1/2 Completed191 enrolled 26 charts
NCT02708680 2024-12-04Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead InSyndax PharmaceuticalsPhase 1/2 Completed89 enrolled 16 charts
NCT02915523 2024-01-10Study of Avelumab With or Without Entinostat in Participants With Advanced Epithelial Ovarian CancerSyndax PharmaceuticalsPhase 1/2 Completed140 enrolled 25 charts